BAMF
DNLI icon

BI Asset Management Fondsmaeglerselskab’s Denali Therapeutics DNLI Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,988
Closed -$41K – 785
2025
Q1 		$41K Buy
+2,988
New +$57.3K ﹤0.01% 833

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's DNLI Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 2,988 shares — an estimated $41K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in DNLI in Q1 2025 and held it in 1 quarter. The position peaked at $41K in Q1 2025. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 2,988 Denali Therapeutics shares in Q2 2025, an estimated $41K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Denali Therapeutics in Q1 2025 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Denali Therapeutics position peaked at $41K in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.